Correlation Between Tcr2 Therapeutics and Akero Therapeutics
Can any of the company-specific risk be diversified away by investing in both Tcr2 Therapeutics and Akero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tcr2 Therapeutics and Akero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Tcr2 Therapeutics and Akero Therapeutics, you can compare the effects of market volatilities on Tcr2 Therapeutics and Akero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tcr2 Therapeutics with a short position of Akero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tcr2 Therapeutics and Akero Therapeutics.
Diversification Opportunities for Tcr2 Therapeutics and Akero Therapeutics
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Tcr2 and Akero is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Tcr2 Therapeutics and Akero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akero Therapeutics and Tcr2 Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tcr2 Therapeutics are associated (or correlated) with Akero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akero Therapeutics has no effect on the direction of Tcr2 Therapeutics i.e., Tcr2 Therapeutics and Akero Therapeutics go up and down completely randomly.
Pair Corralation between Tcr2 Therapeutics and Akero Therapeutics
If you would invest 2,661 in Akero Therapeutics on November 8, 2024 and sell it today you would earn a total of 3,095 from holding Akero Therapeutics or generate 116.31% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Flat |
| Strength | Insignificant |
| Accuracy | 0.0% |
| Values | Daily Returns |
Tcr2 Therapeutics vs. Akero Therapeutics
Performance |
| Timeline |
| Tcr2 Therapeutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
| Akero Therapeutics |
Tcr2 Therapeutics and Akero Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Tcr2 Therapeutics and Akero Therapeutics
The main advantage of trading using opposite Tcr2 Therapeutics and Akero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tcr2 Therapeutics position performs unexpectedly, Akero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will offset losses from the drop in Akero Therapeutics' long position.| Tcr2 Therapeutics vs. Affimed NV | Tcr2 Therapeutics vs. ADC Therapeutics SA | Tcr2 Therapeutics vs. Agenus Inc | Tcr2 Therapeutics vs. Revolution Medicines |
| Akero Therapeutics vs. Terns Pharmaceuticals | Akero Therapeutics vs. Madrigal Pharmaceuticals | Akero Therapeutics vs. Inozyme Pharma | Akero Therapeutics vs. Viking Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |